SINGAPORE – 15 Nov 2024 – Tikva Allocell’s Head of Research – Dr Lionel Low presented a poster on Tikva’s allogenic CAR EBVST platform at the much-anticipated Frontiers in Cancer Science (FCS) conference. Dr Low explained how Tikva overcomes the challenges in preventing graft-versus-host disease (GvHD), enhancing tumor infiltration and the synergistic approach to dual targeting using the transduced B7-H3.CAR and intact EBV-specific T-Cell Receptors (TCRs). He also highlighted how Tikva’s armoring using a modified SerpinB9 molecule – SerpinB9 (CAS), can potentially provide resistance to cell death both in vitro and in vivo.
Lionel LOW, PhD
Head of Research
Lionel is the Head of Research at Tikva Allocell. He brings considerable molecular cell biology experience, specifically in T cell receptor. CAR and antibody discovery and engineering. He is also the inventor of 8 patents and key author on 5 publications.